View Post

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: apnews.com CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled patients were provided to the …

View Post

Imaging technique finds differences between radiation-sensitive and resistant tumors

In Clinical Trials by Barbara Jacoby

Source: University of Arkansas From: sciencedaily.com Researchers have started pilot clinical studies in head and neck cancer patients to determine if Raman spectroscopy, a noninvasive imaging technique, can effectively spare some patients of the toxic side effects of ineffective radiation therapy. Researchers at the University of Arkansas, Johns Hopkins University and the University of Arkansas for Medical Sciences (UAMS) used …

View Post

Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor. This marks the second patient with metastatic cancer observed in full remission (complete response) after treatment …

View Post

Study identifies predictors of immunotherapy response in head and neck cancer

In In The News by Barbara Jacoby

Source: Dana-Farber Cancer Institute From: Redington Newsdesk Dana-Farber Cancer Institute scientists say they have identified factors that predict improved response and survival in patients with head and neck cancers treated with checkpoint inhibitor immunotherapy. Two immunotherapy agents known as checkpoint inhibitors have been approved to treat patients whose disease is resistant to standard platinum-based chemotherapy. However, only a minority of …

View Post

Drug Combination May Improve Impact of Immunotherapy in Head and Neck Cancer

In In The News by Barbara Jacoby

From: UCSD Health Communications Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy’s effectiveness. In a paper published in the journal JCI Insights on September …

View Post

FORMER ONCOLOGY BIOTECH CEO BATTLING TERMINAL CANCER GIVES UNIQUE INSIGHT IN NEW GRIPPING MEMOIR

In In The News by Barbara Jacoby

A Walk With Purpose: Memoir of a Bioentrepreneur By Michael D. Becker “Nothing is as sobering or life-changing as those dreaded words, ‘you have cancer.’ This is a story of a husband, father and bright entrepreneur whose very private struggle with a preventable cancer has been made public with amazing clarity, insight and can’t put-the- book-down humanity.”  -James L Gulley, …

View Post

New Spanish-language videos and brochures provide cancer patients with overview of radiation therapy

In In The News by Barbara Jacoby

From: PR Newswire Cancer patients who speak Spanish have new tools to help them understand treatment options for their disease. The American Society for Radiation Oncology (ASTRO) today released a series of Spanish-language patient videos on radiation therapy for cancer, including breast, prostate, lung, brain and other common cancer types. The videos complement a set of Spanish-language brochures on radiation …

View Post

Head and neck cancer drug ‘game changer’

In In The News by Barbara Jacoby

By: Michelle Roberts From: bbc.com A new type of cancer drug that wakes up the patient’s own immune system to fight tumours could be a game changer for tackling aggressive head and neck cancers, say experts. Trial results coming out of a US cancer conference suggest the treatment works better than standard chemotherapy. Nivolumab significantly improved the survival odds of …

View Post

The Slow, Steady Battle To Fix Cancer Care

In In The News by Barbara Jacoby

By: Carmen Nobel From: forbes.com After a cancer patient’s first 30 days in the American medical system, the bills start stacking up—right next to the pile of paperwork explaining benefits. “It’s very hard for patients to match these things up,” says Dr. Thomas W. Feeley, who recently joined the Harvard Business School faculty as a senior fellow to study health-care …

Immunotherapy: The next frontier in cancer treatment?

In In The News by Barbara Jacoby

From MedCity News by Veciana-Suarez, Ana Though radiation sent Coris Shepard to the hospital with a burned esophagus for 21 days, it did little to the tumors in his left lung. The chemotherapy that followed didn’t work either. In fact, the stubborn cancer actually grew in size. At wit’s end and almost out of hope, he agreed to participate in …